New Heart Medication Approved in England for Obstructive HCM Patients

Aficamten (Myqorzo), a new once-daily pill, has been approved in England for approximately 6,600 patients with obstructive hypertrophic cardiomyopathy (HCM) following coordinated decisions by MHRA and NICE. Clinical trials indicate it improves exercise capacity and reduces symptoms, offering a new treatment option that may require less monitoring than existing therapies. This development provides a significant benefit for patients managing this serious heart condition.